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2Metallo-cryptophane M3L2 cages from cis-linked and trans-linked
strategies.
Trigonal bipyramidal metallo-cage species [Pd3(dppp)3(L)2@Â27IZKHUHGSSS 
bis(diphenylphosphino)propane, OTf = triflate and L is tris(iso-
nicotinoyl)cyclotriguaiacylene (L1) or tris(fluoro-iso-
nicotinoyl)cyclotriguaiacylene (FL1)) have been characterised in solution to
existpredominantly as the anti-isomers. The crystal structure of
[Pd3(dppp)3(FL1)2@Â27IKRZHYHUZDVIRXQGWREHWKHDFKLUDOsyn-isomer. The
complex [Pd3Cl3(L2)2] (where L2 =
tris(methylbenzimidazolyl)cyclotriguaiacylene) is a trans-linked M3L2 cage,
observed by mass spectrometry and in the solid state as the anti-isomer. Ligand
L2 also forms a 1:1 co-crystal with cyclotriguaiacylene.
Keywords: cyclotriveratrylene; metallo-cage; co-crystal; metallo-supramolecular
chemistry
Introduction
Cryptophanes are capsule-like organic cage species composed of two
cyclotriguaiacylene or related fragments linked together through three covalent
spacers.1 They have a rich history as host cage species, and are known to bind gases
such as Xe2 and small hydrocarbons.3 Cyclotriguaiacylene (CTG, Figure 1) is a member
of the cyclotriveratrylene family of host molecules which feature a
tribenzo[a,d,g]cyclononene scaffold with a bowl conformation. CTG is chiral withM
and P isomers, hence crytophanes may form as achiral syn-isomers, or as chiral anti-
isomers (Figure 1). Metallo-cryptophanes, or metallo-organic cryptophanes, are
analogous metallo-cage species of M3L2 composition where L is a CTG-analogue
decorated with transition metal-binding groups. They are one of the smallest metallo-
cages that can be assembled from CTG-type ligands.4 The first metallo-cryptophanes
were reported by Yamaguchi and Shinkai, and their design linked 4-pyridyl-decorated
3L-ligands in a cis-fashion using cis-protected square planar [Pd(PP)] fragments, where
PP = bis(diphenylphosphino)ethane (dppe) or bis(diphenylphosphino)propane (dppp)
(Figure 1).5 Different PP ligands result in different solution behaviour; for
[(Pd3(dppe)3(L)2]6+ a 2.5:1 syn:anti equilibrium mixture results, but where PP = dppp
the initially formed anti-isomer disappears slowly until the syn-isomer predominates in
solution. Chambron and co-workers have recently reported a series of [M3(dppp)3L2]6+
metallo-cryptophanes, where M = Pd(II) or Pt(II) and L is a nitrile-decorated CTG, or
related, ligand (Figure 1b).6 Here, the anti-isomers dominate in solution and the solid
state, although small amounts of syn-isomer were observed for Pt(II) cages. The
[(Pd3(dppe)3(L)2]6+ species where R = H (Figure 1b) converts from anti- to
predominantly syn-isomer when cooled in CD2Cl2,. Research from our laboratories have
employed different metal-chelate motifs to form metallo-cryptophanes with cis-
arrangement of coordination groups. These are [Pd3(bis-NHC)3L2] cages, where bis-
NHC is a naphthyl-appended bis-N-heterocyclic carbene ligand (Figure 1c),7 and
luminescent [{Ir(ppy)2}3L2] cages, where ppy is 2-phenylpyridine (Figure 1d).8 The
former crystallises as achiral syn-isomers, while the latter forms as anti-isomers.
M3L2 metallo-cryptophanes have also been reported without protecting auxillary
chelating ligands from trans coordination of L-ligands at the metal centres, Figure 1e
and 1f. In these examples, linear metal coordination occurred at Ag(I) or Cu(II) cations
with 3-pyridyl or pyrimidine ligand donor groups appended to CTG.9 These trans-
linked cages form as the anti-isomers in the solid state, and the [Ag3L2]3+ metallo-
cryptophane (Figure 1e) actually forms as a [2]catenane of two interlocked cages. Syn-
{(M3L2)2} cage catenane metallo-cryptophanes similarly form with bipyridine-
appended CTG-ligands (Figure 1g).10 M3L2 species related to metallo-cryptophanes can
also be formed from achiral tripodal carboxylate-decorated cavitand ligands.11 Capsule-
4like metallo-cages have also been reported using other types of functionalised bowl-
shaped host molecules, most commonly calix[4]arenes and resorcinarenes, and
including examples of cis-linked 12 and trans-linked 13 and chelate-linked 14 capsules.
We report herein further investigations into both the cis-linked and trans-linked
strategy to metallo-cryptophanes employing the classes of tripodal L-ligands developed
in our laboratories. Such ligands appended with 4-pyridyl groups5,7 (or linear nitrile as
above6) suit the formation of a cis-linked metallo-cryptophane cage, and here we utilise
two ligands appended with iso-nicotinyl groups: tris(iso-nicotinoyl)cyclotriguaiacylene
L1, and tris(fluoro-iso-nicotinoyl)cyclotriguaiacylene (FL1), Scheme 1. CTG-ligands
with iso-nicotinoyl ligand groups have been particularly successful ligands for metallo-
supramolecular chemistry, forming M3L2 metallo-cryptophanes,7 larger M6L8 cages,15
alongside coordination polymers 16 and a M6L6 metallacycle with a unique infinite
Borromean entanglement.17 While previous reports of the trans-linked approach used 3-
pyridyl donors,9 here we investigate a 5-membered imidazole ring as the donor group
with the novel ligand tris(methylbenzimidazolyl)cyclotriguaiacylene (L2, Scheme 1).
5Figure 1: Cyclotriguaiacylene with general form of syn- and anti-cryptophanes and
motifs used to form metallo-cryptophanes with (a)-(d) cis-coordination of CTG-type
ligands at metal; (e)-(f) trans coordination at the metal; (g) from chelating ligand.5-10
Results and Discussion
6Ligand synthesis and structures
The tripodal cyclotriguaiacylene ligands (r)-2,7,12-trimethoxy-3,8,13-tris(3-
fluoro-4-pyridylcarboxy)-10,15-dihydro-5H-tribenzo[a,d,g]cyclononene (tris(fluoro-
iso-nicotinoyl)cyclotriguaiacylene, FL1) and (r)-2,7,12-trimethoxy-3,8,13-
tris(methylbenzimidazol-1-yl)-10,15-dihydro-5H-tribenzo[a,d,g]cyclononene
(tris(methylbenzimidazolyl)cyclotriguaiacylene, L2) were synthesised as racemic
mixtures from cyclotriguaiacylene according to Scheme 1. For FL1, the acid chloride of
3-fluoro-4-pyridine carboxylic acid was generated in situ then reacted with CTG in a
basic environment to give (r)-FL1. Yields are maximised by addition of a second batch
of the acid chloride reactant after an initial 2 days reaction time. Both ligands gave 1H
NMR spectra characteristic of bowl-conformation tripodal CTG derivatives with
retention of high symmetry, and the diastereotopic exo and endo CH2 protons giving
doublets at 4.90 and 3.71 ppm for FL1, and 4.69 and 3.47 ppm for L2. The 19F NMR
spectrum of FL1 is the expected doublet of doublets which collapses to a singlet at -
125.61 ppm in d6-DMSO on broadband decoupling. The anticipated molecular ion
peaks were observed by electrospray mass spectrometry.
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Scheme 1: Ligands used in this study with synthetic routes to FL1 and L2.
7Single crystals of L2 suitable for X-ray analysis were obtained by slow
evaporation of an acetone solution. L2 crystallises in a triclinic cell and the structure
was solved in space group P-1. There is one complete molecule of L2 in the asymmetric
unit. All three methylbenzimidazolyl arms of L2 have different orientations, and are
folded back towards the molecular cavity of L2 effectively blocking any access for
potential guests in this conformation, Figure 2. The Carene-O-CH2-Nimid torsion angles
DUHDQG7KHUHLVDZHDNLQWUDPROHFXODU&+ÂÂÂ1LQWHUDFWLRQEHWZHHQ
WZREHQ]LPLGD]RO\ODW&ÂÂÂ1VHSDUDWLRQc,QWKHFU\VWDOODWWLFHSULPLWLYHOD\HUVRI
L2 ligands form in the ab plane and enantiomeric layers with inverted orientations stack
together in the c direction, (supplementary information (SI) Fig. S39).
Figure 2. X-ray structure of L2 showing asymmetric unit.
Interestingly, L2 forms a co-crystal with its precursor CTG. This was initially
obtained in low yield from the slow evaporation of an acetone solution of L2 containing
some CTG contaminant, but the co-crystal can also be formed in bulk from a 1:1
PL[WXUHRI/DQG&7*7KHVWUXFWXUHRIFRPSOH[/Â&7*ZDVGHWHUPLQHGE\
single crystal X-ray diffraction using a synchrotron source. It crystallises in the non-
centrosymmetric trigonal space group Pc31. The asymmetric unit comprises one third
8of each component, with each molecular component having crystallographic 3-fold
symmetry. Unlike in the structure of L2 itself, the methylbenzimidazolyl arms of L2 are
oriented away from the cavitand bowl. Each molecule of L2 forms hydrogen bonding
DVVRFLDWLRQVZLWKWKUHHHTXLYDOHQW&7*PROHFXOHVWKURXJK2+ÂÂÂ1K\GURJHQERQGVDW
2ÂÂÂ1GLVWDQFHc6LPLODUO\HDFK&7*K\GURJHQERQGVWRWKUHHHTXLYDOHQW/
molecules to form a 2D network of 63 topology, Figure 3a. The CTG and L2 molecules
within the network have opposite orientations of their molecular bowls and each
network is homochiral. Networks pack together in the crystal lattice such that the
chirality of the network alternates along c, and there is homoleptic and racemic bowl-in-
bowl stacking of host molecules - that is, 1-D stacks of L2 molecules of alternating
enantiomer form as do 1-D stacks of enantiomers of CTG, Figure 3b. Bowl-in-bowl
stacking is a well-known motif for cyclotriveratrylene18 though examples of its
occurrence for CTG-analogues are rarer. It does not involve S-S stacking interactions
between the host core and can occur in a racemic fashion as here,15c,19 or involve
formation of homochiral 1-D arrays.15c,20
(a)
9(b)
)LJXUH)URPWKH;UD\VWUXFWXUHRI/Â&7*D6HFWLRQRIDK\GURJHQERQGHG'
network with CTG in green; (b) Stacking between networks highlighting homoleptic
bowl-in-bowl stacking of enantiomers with molecules belonging to one hydrogen
bonded layer in space-filling.
Cis-linked M3L2 cages with L1 or FL1
Use of chelating ligands to control the available coordination sites on the metal is a
common strategy for metallo-cage assembly, most typically to ensure a cis
stereochemistry of available sites. Alongside the bis-phosphines shown in Figure 1, the
most commonly used chelating ligands are ethylenediamine (en) or derivatives.21,22 Our
prior attempts to form M3L2 metallo-cryptophane assemblies, where L =
tris(isonicotinoyl)-tris(propyl)-cyclotricatechylene (R = OPr in Figure 1c), using
[Pd(en)] as cis-protected metal fragments were unsuccessful.7 While a metallo-
cryptophane initially formed, it was metastable and equilibration resulted in
displacement of the chelate ligands and formation of a [Pd6L8]12+ cage. A similar
M3(en)3L2 to M6L8 rearrangement has also been reported by Chand for a different class
of tripodal L ligand.22 Attempts here to form [Pd3(en)3(L)2]6+ species, where L = L1 or
FL1, in a variety of solvents were also unsuccessful. The 1H NMR spectra obtained
10
were a superposition of the spectra of the L and Pd(en)(NO3)2 starting materials (SI
Figs. S11-S13), and a metastable M3L2 species was not observed.
Instead we investigated bis-(diphenylphosphino)propane (dppp) as the cis-
protecting ligand analogous to previous examples.5,6 The square planar complex
[Pd(dppp)(OTf)2] was employed as a cis-protected metallo-tecton for the assembly of a
metallo-cryptophane with the 4-pyridyl-decorated hosts L1 and FL1 according to
Scheme 2. Formation of the [Pd3(dppp)3(L)2]6+ metallo-cryptophane cages, where L =
L1 or FL1, was studied by NMR spectroscopy.
Scheme 2: Self-assembly of [Pd3(dppp)3(L1)2]6+ and [Pd3(dppp)3(FL1)2]6+ cages and
numbering scheme for NMR assignments.
The 1H NMR spectrum of a 3:2 mixture of [Pd(dppp)(OTf)2] and L1 in d3-MeCN is
well-resolved, with slight broadening consistent with complex formation. The spectrum
retains high symmetry typical of a symmetric cage-species such as [Pd3(dppp)3(L1)2]6+.
The 1H Hm peak of L1 was shifted upfield by 0.21 ppm, and the Ha/Hb peaks of dppp,
which are overlapping in the [Pd(dppp)(OTf)2] starting material, are resolved in the
complex which is consistent with spectra of previously reported [Pd3(dppp)3L2]6+
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metallo-cryptophanes.5,6 The propylene Hd peak of the dppp was shifted downfield by
0.26 ppm. The 31P NMR spectrum gave a single peak at ca. 8 ppm. The 2D ROESY 1H
NMR spectrum also gave evidence for metallo-crytophane formation with through-
space connections observed between Ho protons of L1 and Hc and Hb of the dppp,
Figure 5. Whether syn- or anti-[Pd3(dppp)3L2]6+ crytophanes are formed can be
ascertained by behaviour of the He protons. In a D3-symmetric antiisomer cryptophane
a triplet is expected as He protons are homotopic, however they are diastereomeric in
the syn-isomer and two peaks are expected6 in a manner analogous to the NMR signals
observed for –(CH2)n- bridges of E (anti) and F (syn) cryptophanes.23 Here, the He
signal remains a broadened triplet on complexation indicative of the anti-isomer.
Concentration effects on metallo-cage formation were probed with 1H and 31P NMR
spectra recorded at concentrations between 0.5 mmol and 5.0 mmol. As the
concentration increases, small amounts of the syn-isomer can be observed in solution.
31P NMR spectra showed a second broad signal at ca. 10.5 ppm (SI Fig. S14), and close
inspection of the 1H NMR spectrum showed additional sets of broad peaks attributable
to the syn-isomer (Figures 4 and S15). The 5.0 mM solution showed no changes with
temperature and was stable to 65 °C.
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Figure 4. 1H NMR (293 K, 500 MHz, d3-MeCN) spectra of (a) L1; (b)
[Pd(dppp)(OTf)2]; (c) 3:2 mixture of L1 and [Pd(dppp)(OTf)2] forming
[Pd3(dppp)3(L1)2]6+ metallo-cryptophane as predominant anti-isomer, with inset
showing diastereotopic He of syn-isomer observed at 5 mM concentration.
Figure 5. Section of the 1H NMR (293 K, 500 MHz, d3-MeCN) ROESY spectrum of
[Pd3(dppp)3(L1)2@Â27I([FKDQJHSHDNVDUHLQJUH\DQGU2HVLQEODFNZLWKWKURXJK
space connections between L1 and dppp marked.
The [Pd3(dppp)3(L1)2]6+ metallo-cryptophane also assembles in d3-MeNO2, with
both syn- and anti-isomers present in 1:10 proportions at all concentrations studied. The
presence of the syn- isomer was apparent from 1H NMR spectroscopy, with the
13
diastereomeric He signals of the syn- isomer visible (Figure S16). The 2D ROESY
spectrum in d3-MeNO2 was complicated by overlapping peaks, however, through-space
connections between the L1 Ho and Hb of the dppp could be assigned, again consistent
with cage formation (Figure S17).
Assembly of a [Pd3(dppp)3(FL1)2]6+ metallo-cryptophane with the fluorinated
ligand FL1 also occurs in d3-MeNO2 solution. A 3:2 mixture of [Pd(dppp)(OTf)2] and
FL1 in d3-MeNO2 gave a well resolved 1H NMR spectrum, where the FL1 pyridyl Ho
and Ho’ are broadened and shifted downfield, and the Hd proton of the dppp undergoes
a significant downfield shift of 0.42 ppm, Figure 6. 2D ROESY NMR analysis indicates
through-space connections between Hb of the dppp and Ho and Ho’ of the FL1 pyridyl
groups, Fig. S19. It was noted that the resonance for the Hb protons of dppp appeared to
be split into two resonances in the region of 7.7 ppm. This was confirmed by 2-D
HMQC analysis (Fig. S20). 31P NMR spectroscopy indicates a single phosphorous
environment (Fig. S21). This, in addition to the broadened and individual peak for He
dppp proton, indicates that the cage has formed stereoselectively as the anti-isomer. In
this case, increasing concentration of the components in solution up to a maximum of
5.0 mMdid not lead to any changes in the NMR spectra. The 19F{1H} NMR spectrum
revealed at least 5 different fluorine environments, with the most intense and sharpest at
-120.2 ppm, indicating that in solution the C-F groups are in different orientations
within the cryptophane, Fig. S22.
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Figure 6. 1H NMR (293 K, 500 MHz, d3-MeNO2) spectra of (a) FL1; (b)
[Pd(dppp)(OTf)2]; (c) 3:2 mixture of FL1 and [Pd(dppp)(OTf)2] forming
[Pd3(dppp)3(FL1)2]6+ metallo-cryptophane as the anti-isomer.
Combining [Pd(dppp)(OTf)2] and FL1 in d3-MeCN, however, resulted in a 1H
NMR spectrum that closely resembles a superposition of the spectra of the reactants,
Figure S24. Furthermore, the 2D ROESY spectrum showed no through-space
connections between the FL1 and the dppp ligand. Despite NMR studies not giving
compelling evidence of the cage formation in d3-MeCN solution, single crystals of the
metallo-cryptophane [Pd3(dppp)3(FL1)2@Â27IZHUHREWDLQHGIURPYDSRXUGLIIXVLRQRI
Et2O into a MeCN solution of [Pd(dppp)(OTf)2] and FL1 in 3:2 proportions. Their
structure was determined by X-ray diffraction. Interestingly, the marked preference for
an anti-[Pd3(dppp)3(L)2]6+ isomer observed in solution was not reflected in the crystal
structure where the achiral syn-isomer is observed. It should be noted that the product of
a crystallisation is not necessarily under thermodynamic control and depends on
nucleation kinetics, with the first product to nucleate templating further crystal growth.
A mass spectrum of the [Pd3(dppp)3(FL1)2@Â27IFU\VWDOVUHGLVVROYHGLQ&+3CN
showed only a trace peak that was attributable to the cage (Fig. S31).
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The structure of [Pd3(dppp)3(FL1)2@Â27IZDVVROYHGLQWKHWULFOLQLFVSDFH
group P-1 with a complete metallo-cryptophane and counter-anions in the asymmetric
unit. As expected, the Pd(II) centres have approximate square planar geometry with a
chelating dppp ligand (Pd-P bond lengths 2.249(3) to 2.286(3) Å) and coordinating
pyridyl groups from two FL1 ligands of opposite chirality at Pd-N distances ranging
from 2.110(8) to 2.160(8) Å. Each FL1 ligand binds to three Pd(II) centres to form the
cage-like assembly. The cage has a trigonal bipyramidal shape with the Pd(II) cations
IRUPLQJDQHTXDWRULDOSODQHZLWK3GÂÂÂ3GVHSDUDWLRQVFDc5RWDWLRQRIWKHVL[
fluoro-isonicotinoyl groups of the assembly are all slightly different, with the majority
having the carbonyl group exo to the cage cavity and only one with and endo carbonyl.
There is no rotational disorder apparent and positions of the fluorine atoms are well
resolved in an approximately C3-symmetry relationship per FL1 ligand, and with C-F
groups of different FL1 ligands aligning in an eclipsed manner when the cage is viewed
axially.
There are face-to-face S-S stacking interactions between the pyridyl groups of
FL1 and phenyl groups of the dppp, with ring centroid separations 3.43-3.72 Å. These
close interactions are consistent with the through space connections observed by
ROESY NMR in d3-MeNO2. The triflate counter-anions form second sphere
HOHFWURVWDWLFLQWHUDFWLRQVZLWKWKH3G,,FHQWUHVDW62ÂÂÂ3GGLVWDQFHVFDc1RW
all triflate positions could be refined within the structure but electron density difference
maps indicate the excluded anions are also in similar positions around Pd(II) centres. As
for other metallo-cryptophanes there is no evidence of counter-anion encapsulation
inside the cage.6
16
(a)
(b)
Figure 7. From the X-ray structure of [Pd3(dppp)3(FL1)2@Â27IDV\Q
[Pd3(dppp)3(FL1)2]6+ cage viewed down axial direction; (b) space-filling view of cage
from side. Dppp ligands shown in purple.
Trans-linked M3L2 cages with L2
A 3:2 mixture of trans-[PdCl2(MeCN)2] and L2 were reacted in deuterated
dimethylformamide (d7-DMF) or dimethylsulfoxide (d6-DMSO) with the aim of
forming the trans-linked metallo-cryptophane, according to Scheme 3. The 1H NMR
spectra of the resultant solutions were very broad, though a sharp signal was observed
for uncomplexed MeCN which indicates that these have been displaced from the trans-
[PdCl2(MeCN)2] by the imidazolyl-moieties of L2 (SI Figs. S27, S28). However, the
severe broadening and number of signals for the L2 peaks is not indicative of a single,
17
symmetric product. The high resolution electrospray mass spectrum from either solvent
is dominated by a singly charged peak at m/z 941.1833 for species {PdCl(L2)}+.
However, a small peak was also observed at m/z 2134.2070 which corresponds to the
expected isotope pattern for {Pd3Cl5(L2)2(MeCN)}+, the desired metallo-cryptophane
with the loss of one Cl-, Figure 8 and Fig. S32.
Scheme 3: Assembly of trans-linked cage anti-[Pd3Cl6(L2)3] observed by mass
spectrometry and in the solid state.
Figure 8: Detail from ESI-MS of [Pd3Cl5(L2)3]+ observed (top) and calculated
(bottom).
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Single crystals of composition [Pd3Cl6(L2)3Â+22@Â+22Â'0)DUHIRUPHGIURPD
DMF solution containing trans-[PdCl2(MeCN)2] and L2 in 3:2 proportions that was
stirred for 24 hours then subjected to diffusion of diethyl ether vapours. Initially a
yellow powder forms and single crystals form after 3 months. Powder and crystals are
insoluble once precipitated, and powder XRD indicates the powder is amorphous. The
complex crystallises with a cubic unit cell and the structure was solved in space group
Pa-3 and shows the anticipated [Pd3Cl6(L2)3] metallo-cryptophane cage. The structure
has crystallographic 3-fold symmetry with one third of the assembly in the asymmetric
unit, alongside an additional molecule of DMF, a partially occupied H2O exo to the cage
and a disordered water inside the cage.
The Pd(II) centre features trans coordination of terminal Cl- ligands at Pd-Cl
distances 2.2747(15) and 2.2944(15) Å, and two trans benzimidazole groups at Pd-N
distances 2.012(4) and 2.013(5) Å. The two benzimidazole groups belong to
crystallographically distinct L2 ligands and are not coplanar with respect to the
coordinated Pd(II) with torsion angle between the planes ca. 53°. The L2 ligand
coordinates to three symmetry equivalent Pd(II) centres to form a cage-like metallo-
cryptophane assembly, Figure 9. Within a cage assembly, both L2 ligands are of the
same chirality thus the anti-isomer is formed. Overall the structure is racemic. For both
types of L2 ligand, the orientation of the benzimidazole groups with respect to the CTG-
scaffolds are similar, with the benzene moieties exo to the cavitand bowl but the
imidazole CH groups pointing in towards the CTG cavity. Carene-O-CH2-Nimid torsion
angles are 66.3 and 73.4°, and benzimidazole groups of different L2 ligands within the
cage are near co-planar. There are face-to-faceS-S stacking interactions between the
imidazole groups with centroid separation 3.465 Å. The equatorial M3 trigonal plane is
SLQFKHGLQWRZDUGVWKHLQVLGHRIWKHFDSVXOHVWUXFWXUHZLWK3GÂÂÂ3GVHSDUDWLRQVc
19
7KLVFRPSDUHVZLWK3GÂÂÂ3GGLVWDQFHVRIcIRU>3G3(dppp)3(L1)2]6+. This limits
window size and the space available for guest binding within the cage, as can be seen in
the space filling diagram Figure 9b. A molecule of water that was disordered across the
3-fold axis was observed as an intra-cage guest with closest contacts to the imidazole C-
+JURXSVDW&ÂÂÂ2VHSDUDWLRQc&DJHVRIDOWHUQDWLQJFKLUDOLW\SDFNLQD
checkerboard fashion in the crystal lattice, Figure 9c.
Figure 9. From the X-ray structure of [Pd3Cl6(L2)2Â+22@Â+22Â'0)D
[Pd3Cl6(L2)2] metallocryptophane with disordered water guest, hydrogen atoms
omitted for clarity; (b) space filling representation of [Pd3Cl6(L2)2]; (c)checkerboard
arrangement of different enantiomers of the cage.
Experimental
Synthesis
(±)-Cyclotriguaiacylene,24 tris(iso-nicotinoyl)cyclotriguaiacylene (L1),16b and 1-
(chloromethyl)benzimidazole hydrochloride 25 were synthesised by literature methods.
All other chemicals were obtained from commercial sources and were used without
further purification. NMR spectra were recorded by automated procedures on a Bruker
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Avance 300 MHz, 500 MHz NMR or Varian Unity Inova 500 spectrometer.
Electrospray mass spectra (ES-MS) were measured on a Bruker Maxis Impact
instrument in positive ion mode. Infra-red spectra were recorded as solid phase samples
on a Bruker ALPHA Platinum ATR. Elemental analyses were performed on material
WKDWKDGEHHQZDVKHGZLWKGLHWK\OHWKHUVXEVHTXHQWO\GULHGDWÛ&XQGHUYDFXXP
and then exposed to the atmosphere.
(r)-2,7,12-Trimethoxy-3,8,13-tris(3-fluoro-4-pyridylcarboxy)-10,15-dihydro-5H-
tribenzo[a,d,g]cyclononene (FL1). Part 1: 3-Fluoro-4-pyridine carboxylic acid (2.01
g, 12.858 mmol) was suspended in thionyl chloride (12 mL, excess) and heated at reflux
for three hours, during which time it turned from colourless to orange. Excess thionyl
chloride was removed in vacuo to yield 3-fluoro-4-pyridine carbonyl chloride
hydrochloride (980 mg, 4.655 mmol) in quantitative yield which was used without
further purification. Part 2: Anhydrous triethylamine (2.71 mL, 12.40 mmol) was added
to a stirred solution of CTG (645 mg, 1.58 mmol) in anhydrous tetrahydrofuran (240
mL) at -78 qC, under an argon atmosphere. After one hour, 3-fluoro-4-pyridine carbonyl
chloride hydrochloride (980 mg, 4.65 mmol) was added to the reaction mixture and
stirred at -78 qC for a further two hours, before being left to stir at room temperature for
48 hours. A second portion of 3-fluoro-4-pyridine carbonyl chloride hydrochloride (980
mg, 4.65 mmol) was added and left to stir for a further 48 hours, during which time the
reaction mixture discoloured. All volatiles were removed in vacuo, and the resultant
residue triturated in ethanol to afford the target compound as a white solid. Yield 1062
mg, 89 %; m.p. decomposes > 270 qC; HRMS (ES+): m/z 778.2228 {MH}+; calculated
for C42H31F3N3O9 778.2012; 1H NMR (300 MHz, d6-DMSO) G (ppm) = 8.87 (d, 3H,
Ho’, J = 2.3 Hz), 8.69 (d, 3H, Ho, J = 4.9 Hz), 7.97 (dd, 3H, Hm, J = 6.0, 5.1 Hz), 7.58
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(s, 3H, Hf), 7.34 (s, 3H, Hg), 4.90 (d, 3H, Hexo, J = 13.5 Hz), 3.74 (s, 9H, O-CH3), 3.71
(d, 3H, Hendo, J = 13.5 Hz); 19F{1H} NMR (300 MHz, d6-DMSO) G (ppm) = - 125.63;
13C{1H} NMR (75 MHz, d6-DMSO) G (ppm) = 160.3, 158.2, 154.6, 149.0, 146.8, 140.7,
139.1, 137.2, 131.9, 124.4, 123.9, 114.6, 56.3, 34.6; Analysis for
C42H30F3N3O9·0.5(H2O) (% calculated, found) C (64.12, 64.30), H (3.97, 3.85), N (5.34,
5.30); FT-IR (cm-1) 3017, 2976, 2920, 1737, 1607, 1564, 1506, 1442, 1324, 1263, 1205.
(r)-2,7,12-Trimethoxy-3,8,13-tris(methylbenzimidazol-1-yl)-10,15-dihydro-5H-
tribenzo[a,d,g]cyclononene (L2) CTG (400 mg, 0.98 mmol) was added to a
suspension of NaH (60% dispersion in mineral oil) (0.84 g, 20.8 mmol) in anhydrous,
degassed DMF (10 mL) under a nitrogen atmosphere at room temperature, and stirred
for 30 mins. 1-(chloromethyl)benzimidazole hydrochloride (694 mg, 3.4 mmol) was
added in portions and the mixture stirred for 16 h. Water (100 mL) was added and the
resulting grey precipitate filtered. The grey residue was re-dissolved in dichloromethane
(60 mL), dried over MgSO4, and solvents removed in vacuo. The residue was sonicated
in diethyl ether (50 mL), affording the title compound as a white solid. Yield 0.58 g,
0.73 mmol, 75%; HRMS (ESI+) 821.3065 {MNa}+, calculated for {C48H42N6NaO6}+
821.3059; 1H NMR (300 MHz, DMSO-d6įSSPV++1), 7.65 (dd, 3H, J =
6.1, 2.9 Hz, H6) , 7.59-7.55 (m, 3H, H3), 7.25-7.20 (m, 6H, H4, H5), 7.18 (s, 3H, H10),
7.04 (s, 3H, H11), 6.20-6.10 (m, 6H, H8), 4.69 (d, 3H, J = 13.5 Hz, endo-H16), 3.67 (s,
9H, H9), 3.47 (d, 3H, J = 13.6 Hz, exo-H16); 13C{1H} NMR (75 MHz, DMSO-d6į
(ppm) 148.76 (C13), 144.34 (C1), 143.50 (C2), 143.46 (C7), 134.88 (C15), 133.47 (C12),
131.79 (C14), 122.90 (C5), 122.21 (C4), 119.51 (C6), 119.01 (C10), 114.34 (C11), 110.76
(C3), 73.03 (C8), 55.93 (C9), 35.06 (C16); Elemental analysis for C48H42N6O6Â+2O)
Calcd. C 69.79, H 5.50, N 10.18; Found: C 69.82, H 5.01, N 10.32; FT-IR (cm-1) 3092,
2958, 2926, 1611, 1452, 1273, 1198, 970, 745.
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[Pd3(dppp)3(L)2@Â27IFDJHDVVHPEO\
General procedure for NMR experiments: 3:2 stoichiometric mixtures of
[Pd(dppp)(OTf)2] and L-ligand at approximately 5 mM concentration (unless otherwise
specified) were prepared from stock solutions in the appropriate deuterated solvent, and
mixed using a vortex. 1H NMR assignments for representative solution are given below,
details of further experiments are in supplementary information.
[Pd3(dppp)3(L1)2@Â27I1H NMR (500 MHz, d30H&1įSSPįV++R
7.74 (s, 6H, Hm), 7.60 (s, 12H, Hb), 7.50 (7H, s, Ha), 7.39 (s, 12H, Hc), 7.28 (s, 3H,
Hf), 7.07 (s, 3H, Hg), 4.83 (d, 3H, J = 13.7 Hz, Hexo), 3.69 (d, 12H, J = 13.5 Hz,
Hendo+OMe), 3.05 (s, 5H, Hd), 2.24 (s, overlapping with solvent, He).
[Pd3(dppp)3(FL1)2@Â27I1H NMR (500 MHz, d3-MeNO2įSSPV++RR¶
8.69 (s, 3H, Ho/o’), 7.79-7.66 (m, 18H, Hm+Hb), 7.55 (s, 8H, Ha), 7.52-7.38 (m, 15H,
Hc), 7.29 (s, 3H, Hf), 7.07 (s, 3H, Hg), 4.83 (d, 3H, J = 13.7 Hz, Hendo), 3.73 (s, 9H,
OMe), 3.68 (d, 3H, J = 13.9 Hz, Hexo), 3.34 (s, 7H, Hd), 2.49 (s, 3H, He)
Single crystals of [Pd3(dppp)3(FL1)2@Â27IZHUHJURZQE\YDSRXUGLIIXVLRQRIGLHWK\O
ether into a solution of components in acetonitrile. Elemental analysis for
[Pd3(dppp)3(FL1)2@Â27I&DOFG&+1)RXQG&+1
2.10; HRMS (ESI+) m/z 1853.3262 for {[Pd3(dppp)3(FL1)2@Â27I`2+ (minor peak); FT-
IR (cm-1) 1750, 1509, 1436, 1313, 1271, 1244, 1224, 1159, 1097, 1066, 1027, 999, 974,
837, 745, 707, 691, 672, 637, 573, 513.
[Pd3Cl6(L2)2] metallo-cryptophane $VROXWLRQRI/PJȝPRODQG
[PdCl2(MeCN)2@PJȝPROLQ'0)P/ZDVVWLUUHGIRUK7ZRGURSV
were taken for HRMS characterisation, and the rest set up as a vapour diffusion with
diethyl ether anti-solvent. A pale yellow solid precipitated after one week, and small
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number of pale yellow blocks grew after three months. HRMS (ESI+) m/z 941.1833 for
species {PdCl(L2)}+, 2134.21 {Pd6Cl5L2(MeCN)}+ ; FT-IR (cm-1) 1611, 1508, 1264,
1182, 1141, 1066, 1025, 742. Satisfactory microanalysis was not obtained from
powdered material which is likely a mixture of cage and PdCl2: Found C 47.39 H 3.41
N 7.73 % Calcd. for [Pd3Cl6(L2)2] C 54.12, H 3.98, N 7.89; for [Pd3Cl6(L2)2].PdCl2 C
49.96, H 3.67, N 7.29.
X-Ray Crystallography
Crystals were mounted under inert oil on a MiTeGen tip and flash frozen to 150(1) K.
X-ray diffraction data were collected using Cu-KDUDGLDWLRQȜ cXVLQJDQ
Agilent Supernova dual-source diffractometer with Atlas S2 CCD detector and fine-
IRFXVVHDOHGWXEHJHQHUDWRURUXVLQJV\QFKURWURQUDGLDWLRQȜ cDWVWDWLRQ,
RI'LDPRQG/LJKW6RXUFHFRFU\VWDO/Â&7*'DWDZHUHFRUUHFWHGIRU/RUHQ]WLDQ
and polarization effects and absorption corrections were applied using multi-scan
methods. The structures were solved by direct methods using SHELXS-97 and refined
by full- or block-matrix on F2 using SHELXL-97.26 Unless otherwise specified, all non-
hydrogen atoms were refined as anisotropic, and hydrogen positions were included at
geometrically estimated positions. Additional details of data collections and structure
solutions are given below and in Table 1.
/Â&7* Crystals were of poor quality with poor internal consistency (Rint = 0.1652)
and did not diffract to high angles even with the use of synchrotron radiation.
[Pd3(dppp)3(FL1)2@Â27I The Pd, coordinating P atoms and non-hydrogen atoms of
the FL1 ligand were refined as anisotropic, with all other atoms refined with an
isotropic model. Crystals did not diffract at high angles and attempts to grow higher
quality crystals were not successful. Only four of the six triflate counter-anions could be
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located in the difference map and refined, so two have been excluded from refinement
but are included in the formula. One aromatic ring was refined with a rigid body
constraint, some interatomic distances were restrained to be chemically reasonable, and
restraints were placed on some anisotropic displacement parameters. The structure
contained significant void space (ca. 35% of unit cell volume) with residual electron
density which could not be meaningfully modelled as solvent nor counter-anions, hence
the SQUEEZE routine of PLATON was employed.27
[Pd3Cl6(L2)3Â+22@Â+22Â'0) One guest water showed symmetry disorder
across three positions, and another was refined at 0.5 occupancy. Hydrogen positions
were not included for water molecules. Water and DMF solvent were refined
isotropically.
Table 1: Details of X-ray data collections and structure refinements.
Compound
/ /Â&7* >3G3(dppp)3(FL1)2]
Â27I
[Pd3Cl6(L2)3Â+2O)]
Â+22Â'0)
CCDC 1552584 1552583 1552585 1552586
Formula
C48H42N6O6 C72H66N6O12 C171H135F24N6O36P
6Pd3S6
C105H110Cl6N15O17.5
Pd3
Mr 798.88 1207.31 1029.21 2393.98
Crystal size 0.31 x 0.05 x 0.05 0.05 x 0.02 x 0.02 0.07 x 0.05 x 0.01 0.07 x 0.06 x 0.05
Crystal system Triclinic Trigonal Triclinic Cubic
Space group P-1 Pc31 P-1 Pa-3
a (Å) 10.7347(5) 19.4199(10) 18.8882(4) 27.7884(3)
b (Å) 12.6277(4) 19.4119(10) 22.7914(4) 27.7884(3)
c (Å) 14.8026(6) 9.0953(8) 28.1888(6) 27.7884(3)
Į(0) 83.722(3) 90 102.532(2) 90
ȕ(0) 86.985(4) 90 10.5.751(2) 90
Ȗ(0) 79.149(3) 120 93.501(2) 90
V (Å3) 1957.81(14) 2968.1(3) 11307.7(4) 21458.1(4)
Z 2 2 2 8
ȡcalc (g.cm-3) 1.355 1.351 1.176 1.482
ș range (0) 3.58-73.75 2.03-20.14 3.29-65.0 3.18-73.79
No. data collected 15677 23054 89198 19190
No. unique data 7391 2079 37073 7084
Rint 0.0281 0.1652 0.1095 0.0430
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Conclusions
Metal-organic cryptophanes with capsule-like structures were successfully synthesised
using iso-nicotinoyl-appended CTG-ligands and Pd(dppp) as the metal-fragment. The
anti-isomers are the dominant species in solution, and solution assembly was found to
be solvent dependent with [Pd3(dppp)3(L1)2@Â27IREVHUYHGLQERWK&'3CN and
CD3NO2 whilst [Pd3(dppp)3(L1)2@Â27IZDVRQO\VHHQLQ&'3NO2. Nevertheless,
crystals of syn-[Pd3(dppp)3(L1)2@Â27IJUHZIURP&'3CN solution. The inability to
form stable [Pd3(en)3(L)2]6+ capsules, where the protecting chelating ligand is
ethylenediamine, is in keeping with our previous report.7 Cryptophane structures can
also be accessed from metal fragments that have trans available coordination sites,
exemplified by the neutrally charged complex [Pd3Cl6(L2)3] whose crystal structure
revealed formation as the anti-isomer. Here the internal space within the capsule is
limited by the encapsulation of the trans-PdCl2 fragment inside the capsule, however a
water guest was observed inside the cage by crystallography.
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